| silence surrounding hepatitis c status in risk relationships among rural people who use drugs. | hepatitis c virus (hcv) has reached epidemic proportions in rural central appalachia in recent years. we sought to identify demographic, behavioral, and interpersonal characteristics associated with hcv serostatus disclosure among high risk people who use drugs (pwud) in appalachian kentucky. hcv antibody-positive participants (n = 243), drawn from the fifth follow-up assessment of a longitudinal study of rural pwud, completed interviewer-administered questionnaires eliciting demographic and int ... | 2017 | 28733798 |
| Transmission of hepatitis C virus through transplanted organs and tissue - kentucky and massachusetts, 2011. | On September 29, 2011, the United Network for Organ Sharing notified CDC of two patients who tested positive for hepatitis C virus (HCV) infection approximately 6 months after receiving kidney transplants from a deceased donor. Before transplantation, the donor had tested negative for HCV antibody by the organ procurement organization. Tissue also was procured from the donor for possible transplantation. The tissue bank performed an HCV antibody test on the donor's serum specimen that was negati ... | 2011 | 22189891 |
| viral hepatitis and injection drug use in appalachian kentucky: a survey of rural health department clients. | we identified correlates of exposure to hepatitis b and c viruses among health department clients in appalachian kentucky, a rural region noted for high poverty and low education. additionally, we investigated risk factors for transmission, and the frequency of use of preventive measures. | 2010 | 20402204 |
| injection drug users report good access to pharmacy sale of syringes. | to examine injection drug users (idus) opinions and behavior regarding purchase of sterile syringes from pharmacies. | 2002 | 12489619 |
| increases in hepatitis c virus infection related to injection drug use among persons aged ≤30 years - kentucky, tennessee, virginia, and west virginia, 2006-2012. | hepatitis c virus (hcv) infection is the most common blood-borne infection in the united states, with approximately three million persons living with current infection. percutaneous exposure to contaminated blood is the most efficient mode of transmission, and in the united states, injection drug use (idu) is the primary risk factor for infection. state surveillance reports from the period 2006-2012 reveal a nationwide increase in reported cases of acute hcv infection, with the largest increases ... | 2015 | 25950251 |
| healthcare contact and treatment uptake following hepatitis c virus screening and counseling among rural appalachian people who use drugs. | hepatitis c virus (hcv) remains a major contributor to morbidity and mortality worldwide. since 2009, kentucky has led the united states in cases of acute hcv, driven largely by injection drug use in rural areas. improved treatment regimens hold promise of mitigating the impact and transmission of hcv, but numerous barriers obstruct people who inject drugs (pwid) from receiving care, particularly in medically underserved settings. | 2017 | 28648353 |
| increased hepatitis c virus (hcv) detection in women of childbearing age and potential risk for vertical transmission - united states and kentucky, 2011-2014. | hepatitis c virus (hcv) infection is a leading cause of liver-related morbidity and mortality (1). transmission of hcv is primarily via parenteral blood exposure, and hcv can be transmitted vertically from mother to child. vertical transmission occurs in 5.8% (95% confidence interval = 4.2%-7.8%) of infants born to women who are infected only with hcv and in up to twice as many infants born to women who are also infected with human immunodeficiency virus (hiv) (2) or who have high hcv viral load ... | 2016 | 27442053 |
| hepatitis c vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment. | candidate prophylactic hcv vaccines are approaching phase iii clinical trial readiness, yet little is known about the potential for participation among target groups or innovative ways to promote enrollment within 'hard-to-reach' populations. this study describes hcv vaccine trial participation willingness among a high-risk sample of people who use drugs and their willingness to assist researchers by promoting the trial among peers. willingness to participate in and encourage peers' participatio ... | 2015 | 25553715 |
| increases in acute hepatitis b virus infections - kentucky, tennessee, and west virginia, 2006-2013. | as many as 2.2 million persons in the united states are chronically infected with hepatitis b virus (hbv) (1), and approximately 15%-25% of persons with chronic hbv infection will die prematurely from cirrhosis or liver cancer (2). since 2006, the overall u.s. incidence of acute hbv infection has remained stable; the rate in 2013 was 1.0 case per 100,000 persons (3). hepatitis b vaccination is highly effective in preventing hbv infection and is recommended for all infants (beginning at birth), a ... | 2016 | 26821369 |